Loading clinical trials...
Loading clinical trials...
A phase1b/2 Study Evaluating the Efficacy of APR-246, a First-in-class Agent Targeting Mutant p53 in the Treatment of Platinum Resistant Advanced and Metastatic Oesophageal or Gastro-oesophageal Junction Cancers
Conditions
Interventions
APR-246
Locations
5
Australia
Monash Medical Centre
Clayton, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Alfred Hospital
Prahran, Victoria, Australia
Sunshine Hospital Western Health
Sunshine, Victoria, Australia
Start Date
April 11, 2017
Primary Completion Date
October 16, 2020
Completion Date
February 7, 2021
Last Updated
December 13, 2021
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions